A Closer Look At The US Pricing Pushback
This article was originally published in Scrip
Critics of high prescription drug prices are making headlines in the US, and politicians on the presidential campaign trail and on Capitol Hill are talking about government-imposed price controls. But the real news may be unfolding behind the scenes in the private health insurance market, as Cathy Kelly finds out.
You may also be interested in...
Amgen and Sanofi/Regeneron will pay deeper discounts if patients taking Repatha and Praluent don’t experience similar levels of LDL-cholesterol lowering as was seen in clinical trials.
Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.